miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development
Open Access
- 1 February 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1), 19
- https://doi.org/10.1186/s13046-018-0686-6
Abstract
Metastasis is one of the main reasons for treatment failure in endometrial cancer. Notably, high mobility group AT-hook 2 (HMGA2) has been recognized as a driving factor of tumour metastasis. microRNAs (miRNAs) are powerful posttranscriptional regulators of HMGA2. The binding sites of miR-302a-5p and miR-367-3p on HMGA2 mRNA were identified using bioinformatics prediction software and were validated via luciferase assay. The expression levels of miR-302a-5p and miR-367-3p were detected using quantitative real-time PCR and in situ hybridization. Western blotting and immunohistochemistry were used to detect the levels of HMGA2 and epithelial-mesenchymal transition pathway-related proteins. Co-immunoprecipitation was used to detect protein interactions. The roles of miR-302a-5p and miR-367-3p in the regulation of HMGA2 during the progression of endometrial cancer were investigated using both in vitro and in vivo assays. In the present study, high HMGA2 expression was correlated with poor clinical outcomes in endometrial cancer. The binding sites of miRNAs on HMGA2 mRNA were identified using bioinformatics prediction software and were validated via luciferase assay. In the endometrial cancer cell lines Ishikawa and HEC-1A, the overexpression of miR-302a-5p/367-3p significantly inhibited the expression of HMGA2 mRNA. In endometrial cancer tissues, we showed that miR-302a-5p and miR-367-3p were significantly downregulated and thus inversely correlated with HMGA2. The miR-302a-5p and miR-367-3p expression levels were closely correlated with FIGO stage and lymph node metastasis. High expression of miR-302a-5p/367-3p was correlated with high survival rates in endometrial cancer. In addition, miR-302a-5p/367-3p suppressed the malignant behaviour of endometrial carcinoma cells via the inhibition of HMGA2 expression. Our findings indicate that miR-302a-5p/367-3p-mediated expression of HMGA2 regulates the malignant behaviour of endometrial carcinoma cells, which suggests that the miR-302a-5p/367-3p-HMGA2 axis may be a predictive biomarker of endometrial cancer metastasis and patient survival and a potential therapeutic target in metastatic endometrial cancer.Keywords
Funding Information
- The National Natural Science Foundation of China (81272874, 81472438)
- the Department of Science and Technology of Liaoning Province (2013225079)
- Shenyang City Science and Technology Bureau (F14-158-9-47)
- the Outstanding Scientific Fund of Shengjing Hospital (201601)
This publication has 46 references indexed in Scilit:
- MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cellsBMC Cancer, 2013
- miRNA repression of translation in vitro takes place during 43S ribosomal scanningNucleic Acids Research, 2012
- Quantifying negative feedback regulation by micro-RNAsPhysical Biology, 2011
- A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinomaCancer, 2010
- HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinomaLaboratory Investigation, 2010
- HMGA molecular network: From transcriptional regulation to chromatin remodelingBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasisInternational Journal of Cancer, 2009
- Roles of HMGA proteins in cancerNature Reviews Cancer, 2007
- A Novel Role for High-Mobility Group A Proteins in Cellular Senescence and Heterochromatin FormationCell, 2006
- A Differential Gene Expression Profile Reveals Overexpression of RUNX1/AML1 in Invasive Endometrioid CarcinomaCancer Research, 2004